Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Phase 1 Completed 119 enrolled NGM Biopharmaceuticals, Inc

RandomizedFactorialDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and tolerability of NGM282, both single dose and multiple doses, in normal healthy adult participants.

Timeline

Start: 2013-01
Primary completion: 2013-07
Completion: 2013-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aldafermin	Protein / enzyme biologic	—	—

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Summary

Timeline

Drugs

Indications